article thumbnail

STAT Virtual Event: The Next Frontier of Drug Pricing Reform

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. But does the system work for patients? And how can we fix it when it doesn’t? Read the rest…

article thumbnail

STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer

STAT

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines

STAT

WASHINGTON — Medicare officials are still hammering out the technical specifics of how the massive program will start to negotiate drug prices — let alone the substantive ones, Medicare chief Meena Seshamani said at a STAT event Tuesday.

article thumbnail

Cartesian’s CAR-T may help autoimmune patients long term

STAT

I’m writing to you from San Diego, where STAT held an event during the American Academy of Neurology annual meeting this past weekend. We’ll get into a highlight from the event below, along with all the other biotech news today.   Sign up  to get our biotech newsletter in your inbox. Good morning.

article thumbnail

STAT Virtual Event: The State of Biosimilars: What to Watch

STAT

Editor’s note: A livestream of the event will be embedded below at 1 p.m. Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings? What key signals will indicate how biosimilars might be prescribed, or paid for?

article thumbnail

Marks’ exit is not exactly helping industry sentiment

STAT

If you’ll also be there, come to our STAT event on Sunday night! I’ll be talking with researchers about the potential of using GLP-1 drugs for neurological conditions, and my Readout co-writer Meghana will be chatting with BMS’ head of development about the launch of their new schizophrenia drug Cobenfy.

article thumbnail

Sen. Grassley calls on GOP leaders to rally support for PBM reforms

STAT

“They talk in such generalities on this subject that it’s difficult for me to tell where they’re coming from,” he said at a STAT event Wednesday, speaking about top GOP senators’ approach to reforming the drug pricing middlemen who negotiate between pharmaceutical companies and insurers.